Free Trial
NASDAQ:INVO

INVO Bioscience (INVO) Stock Price, News & Analysis

INVO Bioscience logo
$0.75 -0.01 (-1.32%)
(As of 12/20/2024 ET)

About INVO Bioscience Stock (NASDAQ:INVO)

Key Stats

Today's Range
$0.74
$0.78
50-Day Range
$0.73
$1.24
52-Week Range
$0.63
$3.50
Volume
39,601 shs
Average Volume
1.59 million shs
Market Capitalization
$2.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

Receive INVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INVO Bioscience and its competitors with MarketBeat's FREE daily newsletter.

INVO Stock News Headlines

INVO Bioscience (NASDAQ:INVO) Trading Down 3.9% - Here's Why
NAYA Biosciences to present insights into mode of action of NY-303
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
NAYA Biosciences Inc (INVO)
See More Headlines

INVO Stock Analysis - Frequently Asked Questions

INVO Bioscience's stock was trading at $1.35 at the start of the year. Since then, INVO shares have decreased by 44.4% and is now trading at $0.75.
View the best growth stocks for 2024 here
.

INVO Bioscience, Inc. (NASDAQ:INVO) announced its quarterly earnings data on Monday, November, 15th. The company reported ($4.80) earnings per share for the quarter, missing the consensus estimate of ($4.00) by $0.80. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.25 million.

INVO Bioscience's stock reverse split before market open on Thursday, July 27th 2023. The 1-20 reverse split was announced on Thursday, July 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

INVO Bioscience's top institutional shareholders include CWC Advisors LLC. (2.64%). Insiders that own company stock include Andrea Goren, Steve Shum, Michael Jos Campbell and Matthew K Szot.
View institutional ownership trends
.

Shares of INVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that INVO Bioscience investors own include NVIDIA (NVDA), NIO (NIO), Tesla (TSLA), Meta Platforms (META), Nikola (NKLA), Broadcom (AVGO) and Bilibili (BILI).

Company Calendar

Last Earnings
11/15/2021
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:INVO
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Net Income
$-8,030,000.00
Net Margins
-122.79%
Pretax Margin
-122.32%

Debt

Sales & Book Value

Annual Sales
$5.77 million
Book Value
($2.06) per share

Miscellaneous

Free Float
3,769,000
Market Cap
$2.86 million
Optionable
No Data
Beta
1.43
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:INVO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners